RECRUITING

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with prostate cancer.

Official Title

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Advanced Prostate Cancer (CaP)

Quick Facts

Study Start:2024-07-25

Study Completion:2026-07-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06470750

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:MALE

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* GROUP 1 FOCUS GROUPS: * Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer * GROUP 1 SURVEYS: * Are 18 years of age or older * Have histologic evidence of prostate adenocarcinoma * Are requiring, have required, or will require prostate cancer treatment * Have an understanding of the protocol and its requirements * Are willing to fill in a questionnaire and participate in a focused interview * Are able and willing to sign an informed consent * GROUP 1 INTERVIEWS: * Enrollment in the survey phase of the protocol * GROUP 2: * Are 18 years of age or older * Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges) * Have histologic evidence of prostate adenocarcinoma * Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel) * Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW) * Have an understanding of the protocol and its requirements * Are able and willing to sign informed consent	* GROUP 1 FOCUS GROUPS: * Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system * GROUP 1 SURVEYS: * Do not identify as Black men * Have not been diagnosed with prostate cancer * GROUP 1 INTERVIEWS: * Not enrolled in the survey phase of the protocol * GROUP 2: * Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges) * Have not been diagnosed with histologic evidence of prostate adenocarcinoma * Are not requiring active standard anti-cancer therapy

Inclusion Criteria

Exclusion Criteria

* GROUP 1 FOCUS GROUPS:
* Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer
* GROUP 1 SURVEYS:
* Are 18 years of age or older
* Have histologic evidence of prostate adenocarcinoma
* Are requiring, have required, or will require prostate cancer treatment
* Have an understanding of the protocol and its requirements
* Are willing to fill in a questionnaire and participate in a focused interview
* Are able and willing to sign an informed consent
* GROUP 1 INTERVIEWS:
* Enrollment in the survey phase of the protocol
* GROUP 2:
* Are 18 years of age or older
* Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
* Have histologic evidence of prostate adenocarcinoma
* Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel)
* Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW)
* Have an understanding of the protocol and its requirements
* Are able and willing to sign informed consent

* GROUP 1 FOCUS GROUPS:
* Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system
* GROUP 1 SURVEYS:
* Do not identify as Black men
* Have not been diagnosed with prostate cancer
* GROUP 1 INTERVIEWS:
* Not enrolled in the survey phase of the protocol
* GROUP 2:
* Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
* Have not been diagnosed with histologic evidence of prostate adenocarcinoma
* Are not requiring active standard anti-cancer therapy

Contacts and Locations

Study Contact

Clinical Trials Referral Office

CONTACT

855-776-0015

mayocliniccancerstudies@mayo.edu

Principal Investigator

Roxana S. Dronca, MD

PRINCIPAL_INVESTIGATOR

Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980

United States

Collaborators and Investigators

Sponsor: Mayo Clinic

Roxana S. Dronca, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-25

Study Completion Date2026-07-30

Study Record Updates

Study Start Date2024-07-25

Study Completion Date2026-07-30

Terms related to this study

Additional Relevant MeSH Terms

Prostate Adenocarcinoma